Confirmation of Interim Results
11/08/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220811:nRSK6310Va&default-theme=true
RNS Number : 6310V Tissue Regenix Group PLC 11 August 2022
Tissue Regenix Group plc
("Tissue Regenix" or the "Group")
Confirmation of Interim Results
Investor Presentation
Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms
it will issue its interim results for the six months ended 30 June 2022 on
Wednesday 7 September 2022.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer,
will be hosting a live online presentation relating to the interim results via
the Investor Meet Company platform at 4.30pm on Wednesday 7 September 2022.
The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the
presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
(https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor)
Investors who already follow Tissue Regenix on the Investor Meet Company
platform will automatically be invited.
For more information:
Tissue Regenix Group plc www.tissueregenix.com (http://www.tissueregenix.com)
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Tel: +44(0)20 7710 7600
Ben Maddison / Nicholas Harland
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 TissueRegenix@walbrookpr.com
Alice Woodings / Lianne Applegarth
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation ('dCELL®')
technology removes DNA and other cellular material from animal and human soft
tissue leaving an acellular tissue scaffold which is not rejected by the
patient's body and can then be used to repair diseased or worn out body parts.
Current applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech
company that specializes in regenerative medicine and is dedicated to the
development of innovative osteoinductive and wound care scaffolds that enhance
healing opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general orthopaedic, foot
& ankle, dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORURAWRUNUWAAR